ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that NHS Western Isles Hospital in Stornaway is the first hospital in Scotland to incorporate the ZOLL AutoPulse® Non-invasive Cardiac Support Pump for use in cardiac arrest and resuscitation.
The AutoPulse is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA).
“NHS Western Isles recognizes the contribution the AutoPulse can make in improving patient care and survival rates from sudden cardiac arrest, which is why we made the decision to become the first Health Board in Scotland to implement the device,” said Gordon Jamieson, NHS West Isles Chief Executive. “The importance of being able to provide continuous, high-quality chest compressions during emergency situations—while also freeing up clinical and medical staff to attend to the critical needs of patients—is immeasurable when every second counts.”
“The AutoPulse allows rescuers to provide compressions in a ‘hands-free’ manner while performing other life-saving activities. It delivers improved blood flow without interruptions or rescuer fatigue,” added Emma-Jane Trayner, the hospital’s Resuscitation and Clinical Skills Facilitator. “It also gives caregivers better access to the patient, resulting in the possibility of improved survival from cardiac arrest.”
The AutoPulse will be located in the hospital’s Accident and Emergency Deparatment for use as required. Additional devices are being considered to support emergency services in other hospital departments.
About the AutoPulse
The AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion. It may offer a significant advantage over manual CPR, moving blood more consistently than human providers. Additionally, it offers the benefit of freeing up clinicians and rescuers to focus on other life-saving interventions.
Nearly 6,000 AutoPulse devices are in use in hospitals and emergency service organizations worldwide.
About Sudden Cardiac Arrest
SCA, an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs, claims more than 1 million lives globally each year. It is the leading cause of unexpected death in the world and strikes without warning. Survival is poor in most communities at less than eight percent and improvements in resuscitation practices could save as many as half of these victims.
About NHS Western Isles Hospital
NHS Western Isles Hospital (nhs.uk) is a 212-bed rural general hospital in Stornoway in the Western Isles of Scotland run by NHS Western Isles, the local health board. The rural general hospital is a concept unique to the National Health Service in Scotland. A rural general hospital is a small hospital, similar to a district general hospital, that serves an area which is remote and rural, generally with a small population, which would otherwise have a long or difficult journey to access secondary care. The Western Isles is an archipelago of 11 populated islands located 40 miles off the North West coast of Scotland, and is 130 miles long from the Butt of Lewis in the North to the Isle of Barra in the South.
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com) develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe.
Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL is a registered trademark of ZOLL Medical Corporation in the United States and/or other countries. NorthFace ScoreBoard Award is a service mark of Omega Management Group Corporation. All product names are the property of their respective owners.
Jill Garratt, ZOLL Medical UK Ltd
P: +44 01928 595 160 / E: jgarratt[.]zoll.com.